JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Simulations Plus Inc

Închisă

SectorSănătate

14.52 2.11

Rezumat

Modificarea prețului

24h

Curent

Minim

14.42

Maxim

14.6

Indicatori cheie

By Trading Economics

Venit

3.9M

4.5M

Vânzări

5.9M

24M

EPS

0.35

Randament dividend

0.48

Marjă de profit

18.669

Angajați

212

EBITDA

4.9M

7.2M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+9.89% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.48%

2.24%

Următoarele câștiguri

13 iul. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

51M

302M

Deschiderea anterioară

12.41

Închiderea anterioară

14.52

Sentimentul știrilor

By Acuity

26%

74%

88 / 348 Clasament în Healthcare

Simulations Plus Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2026, 19:19 UTC

Achiziții, Fuziuni, Preluări

Intertek Group Rejects EQT's Revised Offer

24 apr. 2026, 23:37 UTC

Achiziții, Fuziuni, Preluări

Scoring the Cook Era -- Barrons.com

24 apr. 2026, 20:51 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 20:50 UTC

Market Talk
Evenimente importante

Financial Services Roundup: Market Talk

24 apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 apr. 2026, 20:39 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 20:09 UTC

Câștiguri

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 apr. 2026, 19:48 UTC

Market Talk
Evenimente importante

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 apr. 2026, 19:25 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 19:25 UTC

Achiziții, Fuziuni, Preluări

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 apr. 2026, 19:22 UTC

Câștiguri

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 apr. 2026, 19:06 UTC

Câștiguri

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 apr. 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 apr. 2026, 18:30 UTC

Achiziții, Fuziuni, Preluări

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 apr. 2026, 18:28 UTC

Achiziții, Fuziuni, Preluări

Intertek Rejects Revised EQT Offer

24 apr. 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 apr. 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 apr. 2026, 17:42 UTC

Câștiguri

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 apr. 2026, 17:28 UTC

Câștiguri

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 apr. 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 apr. 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24 apr. 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 apr. 2026, 17:09 UTC

Market Talk
Câștiguri

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 apr. 2026, 17:09 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 17:06 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 apr. 2026, 16:51 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 apr. 2026, 16:20 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

24 apr. 2026, 16:20 UTC

Market Talk
Evenimente importante

Financial Services Roundup: Market Talk

24 apr. 2026, 16:20 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

24 apr. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Comparație

Modificare preț

Simulations Plus Inc Așteptări

Obiectiv de preț

By TipRanks

9.89% sus

Prognoză pe 12 luni

Medie 16 USD  9.89%

Maxim 16 USD

Minim 16 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSimulations Plus Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

2

Cumpărare

1

Păstrare

0

Vânzare

Sentiment

By Acuity

88 / 348 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat